Jonas Klingström

The paper identifies 70 antiviral compounds against Puumala Orthohantavirus through a drug repurposing screen in human cell lines.

This study identifies altered DNA methylation patterns in the upper respiratory airway of COVID-19 patients, highlighting changes in immune-related genes and potential implications for airway health.

This study shows that SARS-CoV-2 and HSV-1 induce amyloid aggregation of proteins in human CSF, leading to soluble protein depletion, suggesting a potential mechanism linking viral infections to neurodegenerative diseases.

This study identifies virapinib, a novel inhibitor of macropinocytosis that blocks viral entry by SARS-CoV-2, Monkeypox virus, and TBEV without host cell toxicity.

This study shows that a monovalent XBB.1.5-adapted BNT162b2 booster vaccine enhances binding and neutralizing antibodies against XBB.1.5 and BA.2.86 in elderly individuals with prior vaccinations.

This paper shows that clinical-grade soluble ACE2 effectively inhibits multiple SARS-CoV-2 variants, including VOCs, in cell cultures and across independent labs.

The paper shows clinical grade recombinant ACE2 effectively neutralizes SARS-CoV-2 Omicron in VeroE6 cells, outperforming neutralization against reference isolates.